…was one of the first companies to uncover PIKfyve, a novel target for amyotrophic lateral sclerosis (ALS), and to develop a treatment candidate in-house. That investigational ALS treatment is expected to begin clinical testing later this year, just four years after the target’s identification.
Read MoreFierce Biotech Names Verge Genomics a 2022 “Fierce 15” Biotech Company
Read More
Verge Genomics Chief Business Officer, Jane Rhodes, PhD, to participate in Fierce Biotech Summit panel: Leverage AI and ML to advance discovery and accelerate drug development.
Read More